Haemonetics Corporation (NYSE:HAE) Delivers Margin Expansion, Forces Near-Term Valuation Reassessment
![]() |
Haemonetics enters the period with improving profitability and ample cash, while elevated leverage and bearish momentum compress near-term upside. Valuation metrics imply WMDST’s under-valued assessment faces technical resistance before re-rating. |









